Vascular Biogenics Ltd. Stock News

Shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $2.24 and traded as low as $2.05. Vascular Biogenics shares last traded at $2.06, with a volume of 296,919 shares traded. Several research analysts recently commented on the company. HC []

The FDA raises concerns related to data in Reata's (RETA) NDA seeking approval for bardoxolone for treating Alport syndrome. An advisory committee meeting is scheduled tomorrow.

Zacks Investment Research lowered shares of Vascular Biogenics (NASDAQ:VBLT) from a buy rating to a hold rating in a research note released on Thursday, Zacks.com reports. According to Zacks, Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its []

Vascular Biogenics (NASDAQ:VBLT) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a note issued to investors on Thursday, Zacks.com reports. According to Zacks, Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. []

Vascular Biogenics (NASDAQ:VBLT) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability. Insider & Institutional Ownership 6.2% of Vascular Biogenics shares are held by institutional investors. Comparatively, []

HC Wainwright reiterated their buy rating on shares of Vascular Biogenics (NASDAQ:VBLT) in a report released on Tuesday, PriceTargets.com reports. HC Wainwright currently has a $4.00 price objective on the biopharmaceutical companys stock. Separately, Zacks Investment Research cut Vascular Biogenics from a hold rating to a sell rating in a report on Tuesday, October 19th. []

Vascular Biogenics Ltd. (NASDAQ:VBLT) Equities research analysts at Oppenheimer increased their FY2021 EPS estimates for Vascular Biogenics in a note issued to investors on Monday, November 15th. Oppenheimer analyst K. Degeeter now anticipates that the biopharmaceutical company will post earnings per share of ($0.41) for the year, up from their previous estimate of ($0.43). []

Vascular Biogenics (VBLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Vascular Biogenics (VBLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Vascular Biogenics (NASDAQ:VBLT) posted its earnings results on Monday. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02, Fidelity Earnings reports. Vascular Biogenics had a negative return on equity of 69.23% and a negative net margin of 3,546.69%. During the same period in the prior […]

HC Wainwright reaffirmed their buy rating on shares of Vascular Biogenics (NASDAQ:VBLT) in a report issued on Tuesday morning, Price Targets.com reports. The firm currently has a $4.00 price objective on the biopharmaceutical companys stock. Separately, Zacks Investment Research downgraded Vascular Biogenics from a hold rating to a sell rating in a report on Tuesday, []

Vascular Biogenics (NASDAQ:VBLT) released its quarterly earnings data on Sunday. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02, Fidelity Earnings reports. Vascular Biogenics had a negative return on equity of 69.23% and a negative net margin of 3,546.69%. During the same quarter last year, []

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 10.00% and -0.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q3 2021 Results - Earnings Call Transcript